OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway. It has strategic alliances with Celgene Corporation for discovery, development, and commercialization of novel small molecule therapeutics; and Bayer Pharma AG for discovery, development, and commercialization of anti- cancer stem cell biologic and small molecule therapeutics targeting the Wnt signaling pathway. OncoMed Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Redwood City, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OMED
Previous Symbol
CUSIPN/A
Phone650-995-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio3.43
Quick Ratio3.43
Price-To-Earnings
Trailing P/E Ratio-0.77
Forward P/E Ratio-2.58
P/E GrowthN/A
Sales & Book Value
Annual Sales$38.15 million
Price / Sales0.81
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.28) per share
Price / Book-0.63
Profitability
EPS (Most Recent Fiscal Year)($1.04)
Net Income$-39,060,000.00
Net Margins10.98%
Return on Equity25.81%
Return on Assets6.54%
Miscellaneous
Employees56
Outstanding Shares38,630,000
Market Cap$30.52 million
OptionableOptionable
Oncomed Pharmaceuticals (NASDAQ:OMED) Frequently Asked Questions
What is Oncomed Pharmaceuticals' stock symbol?
Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."
How were Oncomed Pharmaceuticals' earnings last quarter?
Oncomed Pharmaceuticals Inc (NASDAQ:OMED) released its earnings results on Thursday, November, 1st. The biopharmaceutical company reported $0.16 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.36. The biopharmaceutical company earned $19.52 million during the quarter, compared to analyst estimates of $7.97 million. Oncomed Pharmaceuticals had a return on equity of 25.81% and a net margin of 10.98%. View Oncomed Pharmaceuticals' Earnings History.
When is Oncomed Pharmaceuticals' next earnings date?
What price target have analysts set for OMED?
3 Wall Street analysts have issued twelve-month price targets for Oncomed Pharmaceuticals' stock. Their forecasts range from $1.50 to $6.00. On average, they anticipate Oncomed Pharmaceuticals' share price to reach $3.1667 in the next year. This suggests a possible upside of 295.6% from the stock's current price. View Analyst Price Targets for Oncomed Pharmaceuticals.
What is the consensus analysts' recommendation for Oncomed Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncomed Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncomed Pharmaceuticals.
Has Oncomed Pharmaceuticals been receiving favorable news coverage?
News headlines about OMED stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Oncomed Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Oncomed Pharmaceuticals' key competitors?
Some companies that are related to Oncomed Pharmaceuticals include Syndax Pharmaceuticals (SNDX), XOMA (XOMA), DURECT (DRRX), Catalyst Biosciences (CBIO), Spero Therapeutics (SPRO), Mersana Therapeutics (MRSN), Selecta Biosciences (SELB), Tiziana Life Sciences (TLSA), Sol Gel Technologies (SLGL), Sesen Bio (SESN), Sierra Oncology (SRRA), Iterum Therapeutics (ITRM), Cue Biopharma (CUE), Chembio Diagnostics (CEMI) and Eton Pharmaceuticals (ETON).
Who are Oncomed Pharmaceuticals' key executives?
Oncomed Pharmaceuticals' management team includes the folowing people:
- Mr. Perry A. Karsen, Exec. Chairman (Age 63)
- Dr. John A. Lewicki, Pres, CEO & Director (Age 66)
- Dr. Austin Gurney, Chief Scientific Officer & Sr. VP (Age 54)
- Dr. Alicia J. Hager, Sr. VP & Gen. Counsel (Age 48)
- Ms. Yvonne Li, VP of Fin. & Admin. and Controller (Age 58)
Who are Oncomed Pharmaceuticals' major shareholders?
Oncomed Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (14.75%), Renaissance Technologies LLC (2.12%), Nexthera Capital LP (1.64%), Essex Investment Management Co. LLC (0.25%), Dimensional Fund Advisors LP (0.24%) and Alambic Investment Management L.P. (0.14%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Jack W Lasersohn, John A Lewicki, Jonathan D Root, Paul J Hastings, Perry A Karsen, Sunil Patel, Timothy Hoey and Yvonne Li. View Institutional Ownership Trends for Oncomed Pharmaceuticals.
Which major investors are selling Oncomed Pharmaceuticals stock?
OMED stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P.. Company insiders that have sold Oncomed Pharmaceuticals company stock in the last year include Alicia J Hager, John A Lewicki and Yvonne Li. View Insider Buying and Selling for Oncomed Pharmaceuticals.
Which major investors are buying Oncomed Pharmaceuticals stock?
OMED stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Primecap Management Co. CA, Essex Investment Management Co. LLC, Dimensional Fund Advisors LP and Renaissance Technologies LLC. Company insiders that have bought Oncomed Pharmaceuticals stock in the last two years include Jack W Lasersohn and Perry A Karsen. View Insider Buying and Selling for Oncomed Pharmaceuticals.
How do I buy shares of Oncomed Pharmaceuticals?
Shares of OMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncomed Pharmaceuticals' stock price today?
One share of OMED stock can currently be purchased for approximately $0.8005.
How big of a company is Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals has a market capitalization of $30.52 million and generates $38.15 million in revenue each year. The biopharmaceutical company earns $-39,060,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Oncomed Pharmaceuticals employs 56 workers across the globe.
What is Oncomed Pharmaceuticals' official website?
How can I contact Oncomed Pharmaceuticals?
Oncomed Pharmaceuticals' mailing address is 800 Chesapeake Drive, Redwood City CA, 94063. The biopharmaceutical company can be reached via phone at 650-995-8200 or via email at [email protected]
MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ OMED)
MarketBeat's community ratings are surveys of what our community members think about Oncomed Pharmaceuticals and other stocks. Vote "Outperform" if you believe OMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
